Palantir stock falls on UK NHS contract scrutiny
Palantir Technologies Inc. shares declined on Wednesday amid regulatory scrutiny of its UK NHS Federated Data Platform contract. The UK's Office for Statistics Regulation addressed concerns over performance metrics, leading NHS England to add caveats and commission an independent review. Criticism from the Good Law Project and regional opt-outs further pressure the contract, while the stock trades below key moving averages ahead of its Aug. 3 earnings report.

*this image is generated using AI for illustrative purposes only.
Palantir Technologies Inc. (NYSE: PLTR) stock fell on Wednesday, driven by targeted regulatory scrutiny regarding its UK National Health Service (NHS) Federated Data Platform (FDP) contract. The decline occurred as the Technology sector emerged as the weakest performer of the day, down 0.4%, while the Nasdaq dipped 0.21% and the S&P 500 gained 0.11%. The regulatory pressure highlights potential risks to Palantir's government contracts, which are a critical component of its revenue base.
UK Regulator Addresses FDP Metrics
The UK’s Office for Statistics Regulation (OSR) addressed public concerns on Wednesday regarding NHS England’s communication of performance metrics for the FDP. On June 6, NHS England updated its methods page to include the statement: "We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for." The OSR noted that this caveat was added following Freedom of Information requests regarding FDP data analysis. In response to the scrutiny, NHS England committed to placing caveats on its main FDP website and commissioning Imperial College to conduct an independent academic evaluation.
Contract Controversies and Criticism
The regulatory developments follow broader scrutiny over the NHS contract. Jo Maugham, executive director of the Good Law Project, stated: "Palantir is not — and frankly never has been — a company that can be trusted with this nationally important contract." Additionally, regional NHS entities have opted out of the system. In a Guardian letter published on July 20, Dr. Devan Moodley, CEO of Health Connect Global, highlighted that Greater Manchester’s integrated care board declined the platform, relying instead on local capabilities built with UK universities and firms.
Financial Results and Technical Analysis
Palantir is scheduled to report its second-quarter financial results on Aug. 3. Analysts project earnings per share of 33 cents on quarterly revenue of $1.81 billion. From a technical perspective, the stock is facing resistance as it trades below key moving averages. The stock is 2.9% below its 50-day SMA ($132.22) and 17.1% below its 200-day SMA ($154.84), maintaining a bearish bias. The 20-day SMA ($126.81) sits just below the current price, but the 20-day remains below the 50-day, and the "Death Cross" formed in February continues to pressure rallies. The Relative Strength Index (RSI) stands at 47.37, indicating neutral momentum.
| Technical Metric | Value |
|---|---|
| 50-day SMA | $132.22 |
| 200-day SMA | $154.84 |
| 20-day SMA | $126.81 |
| RSI | 47.37 |
| Key Resistance | $136.50 |
| Key Support | $122.50 |
At the time of publication on Wednesday, Palantir Technologies shares were down 4.93% at $126.12.
How might the outcome of the Imperial College evaluation influence the UK government's decision to extend or expand Palantir's NHS contract?
Could the opt-out by regional entities like Greater Manchester encourage other NHS trusts to seek local alternatives, potentially reducing Palantir's total addressable market in the UK?
Will the increased regulatory scrutiny in the UK impact Palantir's ability to secure similar government contracts in other European jurisdictions?

































